Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | GBA1 | P04062 | 2/20 | 0.43 |
| ▸ | UGCG | Q16739 | 2/20 | 0.43 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | NAAA | Q02083 | 3/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL581027 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRHRH4HRH3 | |
| SCHEMBL879887 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRHRH4HRH3 | |
| SCHEMBL1309167 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRHRH4HRH3 | |
| SCHEMBL517888 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRHRH4HRH3 | |
| SCHEMBL31490075 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRHRH4HRH3 | |
| SCHEMBL7564811 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRHRH4HRH3 | |
| SCHEMBL580258 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRHRH4HRH3 | |
| SCHEMBL4229986 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRHRH4HRH3 | |
| SCHEMBL5619569 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRHRH4HRH3 | |
| SCHEMBL5857276 | 0.98 | L3MBTL1 (0.53) | L3MBTL1TDP1TSHRHRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4036079-B1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX INC (US) | 2025-11-19 | — | — | EP | disclosed |
| US-12396961-B2 | Compounds and compositions for intracellular delivery of agents | MODERNATX, INC. (US) | 2025-08-26 | — | — | US | disclosed |
| EP-3394030-B2 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX INC (US) | 2025-02-12 | — | — | EP | disclosed |
| EP-4036079-A2 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | ModernaTX, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| EP-3394030-B1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX INC (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3394030-B1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX INC (US) | 2021-12-22 | — | — | EP | disclosed |
| US-20210161829-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2021-06-03 | — | — | US | disclosed |
| US-10799463-B2 | Compounds and compositions for intracellular delivery of agents | MODERNATX, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10195156-B2 | Compounds and compositions for intracellular delivery of agents | MODERNATX, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20180369419-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | Moderna TX, Inc. (US) | 2018-12-27 | — | — | US | disclosed |
| US-20130267546-A1 | Multifunctional Radical Quenchers and Their Uses | Arizona Board of Regents, a body corporate of the State of Arizona acting for and on behalf of Ari (US) | 2013-10-10 | — | — | US | disclosed |
| US-20130267546-A1 | Multifunctional Radical Quenchers and Their Uses | Arizona Board of Regents, a body corporate of the State of Arizona acting for and on behalf of Ari (US) | 2013-10-10 | — | — | US | disclosed |
| EP-2536690-A1 | MULTIFUNCTIONAL RADICAL QUENCHERS AND THEIR USE | Arizona Board Of Regents (US) | 2012-12-26 | — | — | EP | disclosed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
| EP-2433940-A1 | SPIROIMIDAZOLONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2012-03-28 | — | — | EP | disclosed |
| EP-2433940-A1 | SPIROIMIDAZOLONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2012-03-28 | — | — | EP | disclosed |
| WO-2011103536-A1 | MULTIFUNCTIONAL RADICAL QUENCHERS AND THEIR USE | ARIZONA BOARD OF REGENTS (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2010126030-A1 | SPIROIMIDAZOLONE DERIVATIVE | 中外製薬株式会社 (JP) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10195156-B2 | Compounds and compositions for intracellular delivery of agents | LNPK, PLTP, PHOSPHO1 | L3MBTL1 723/4885TDP1 3837/4885TSHR 3222/4885 |
| US-20130267546-A1 | Multifunctional Radical Quenchers and Their Uses | SQOR, GSR, GPX4 | L3MBTL1 2443/4885TDP1 752/4885TSHR 3329/4885 |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | WNK3, REN, SGK3 | L3MBTL1 4219/4885TDP1 3062/4885TSHR 914/4885 |
| US-12396961-B2 | Compounds and compositions for intracellular delivery of agents | LNPK, PLTP, PHOSPHO1 | L3MBTL1 723/4885TDP1 3837/4885TSHR 3222/4885 |
| US-20180369419-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | LNPK, PLTP, PHOSPHO1 | L3MBTL1 723/4885TDP1 3837/4885TSHR 3222/4885 |
| US-20210161829-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | LNPK, PLTP, PHOSPHO1 | L3MBTL1 723/4885TDP1 3837/4885TSHR 3222/4885 |
| US-10799463-B2 | Compounds and compositions for intracellular delivery of agents | LNPK, PLTP, PHOSPHO1 | L3MBTL1 723/4885TDP1 3837/4885TSHR 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.